Barclays’s Roivant Sciences ROIV Stock Holding History

Barclays’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,100	Closed	-$16.6K	–	5610
2025 Q3	$16.6K	Buy	+1,100	New	+$13.6K	﹤0.01%	4967

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Barclays's ROIV Position: Q2 2026 in Review

Barclays reduced its Roivant Sciences (ROIV) stake by 70% in Q2 2026, selling an estimated $29.2M and leaving 426,685 shares worth $15.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1284.

Barclays first reported a position in ROIV in Q1 2022 and has held it in 18 quarters since. The position peaked at $39.2M in Q1 2026. 500 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Barclays held 426,685 shares of Roivant Sciences worth $15.1M as of Q2 2026.
Barclays sold 989,163 Roivant Sciences shares in Q2 2026, an estimated $29.2M.
Roivant Sciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1284 holding.
Barclays first reported a position in Roivant Sciences in Q1 2022 and has held it in 18 quarters since.
Barclays's Roivant Sciences position peaked at $39.2M in Q1 2026.
500 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.